SCHEMBL9254409

SCHEMBL9254409

CC(C)c1ccc(-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.59
SRD5A2 P31213 1/20 0.49
HSD11B1 P28845 2/20 0.45
PRKAB2 O43741 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAG3 Q9UGI9 1/20 0.43
PRKAG2 Q9UGJ0 1/20 0.43
PRKAB1 Q9Y478 1/20 0.43
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
HTT P42858 1/20 0.42
MARS1 P56192 2/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
DAGLA Q9Y4D2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9257913 0.84 PRKAB2 (0.43) AHRPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL9876894 0.83 ADRB2 (0.50) AHRLMNATP53
SCHEMBL2933108 0.83 AHR (0.67) AHRSRD5A2HSD11B1TP53MARS1
SCHEMBL14670096 0.82 LMNA (0.48) AHRHSD11B1PRKAB2PRKAG1PRKAA2
SCHEMBL29446792 0.81 HSP90AA1 (0.48) AHRHSD11B1LMNACNR1CNR2
SCHEMBL4349472 0.81 HSP90AA1 (0.48) AHRHSD11B1LMNACNR1CNR2
SCHEMBL11542148 0.81 AHR (0.47) AHRSRD5A2HSD11B1PRKAB2PRKAG1
SCHEMBL12418420 0.81 APP (0.49) LMNA
SCHEMBL11489253 0.80 AHR (0.46) AHRSRD5A2HSD11B1LMNATP53
SCHEMBL7136627 0.79 AHR (0.57) AHRSRD5A2HSD11B1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783494-B2 Glucagon antagonists METABASIS THERAPEUTICS, INC. (US) 2017-10-10 US disclosed
EP-3153501-A1 GLUCAGON ANTAGONISTS Metabasis Therapeutics, Inc. (US) 2017-04-12 EP disclosed
US-20130030029-A1 Glucagon Antagonists METABASIS THERAPEUTICS, INC. (US) 2013-01-31 US disclosed
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND SHIONOGI & CO., LTD. (JP) 2012-05-31 US disclosed
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND SHIONOGI & CO., LTD. (JP) 2012-05-31 US disclosed
US-7964643-B2 Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2011-06-21 US disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130030029-A1 Glucagon Antagonists GLP1R, GCG, GCGR AHR 541/4885SRD5A2 720/4885HSD11B1 312/4885
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND BACE1, STS, APP AHR 987/4885SRD5A2 1580/4885HSD11B1 702/4885
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L AHR 62/4885SRD5A2 885/4885HSD11B1 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.